Functional Markers of Vascular Aging: Subendocardial Viability Ratio, Augmentation Pressure, and Augmentation Index as Links to Atherosclerotic Cardiovascular Disease Risk Authors: Lan Yang, Lingxiao Wang, Jing Ma, Ning Wang, Rong Yu, Tianyu Wu, Huiyong Hu, Hairong Wang, Xianghong Luo, Zhaojun Li Published: 2026 ABSTRACT ABSTRACTThis study investigated the correlation of functional hemodynamic parameters, including subendocardial viability ratio (SEVR), augmentation pressure (AP) and heart‐rate‐corrected augmentation index (Aix@75), with age and atherosclerotic cardiovascular disease (ASCVD) risk in a Chinese population. A total of 3,354 participants aged 18–80 years with left ventricular ejection fraction >55% were enrolled in this cross‐sectional study. Functional hemodynamic parameters were assessed by pulse wave analysis, and the 10‐year ASCVD risk (10Y‐ASCVDR) was estimated using the China‐PAR model. Multivariable logistic regression was used to identify independent correlates of elevated estimated 10Y‐ASCVDR. Results showed that 10Y‐ASCVDR was inversely correlated with SEVR (r = –0.171, p < 0.001) and positively correlated with AP (r = 0.452, p < 0.001) and Aix@75 (r = 0.236, p < 0.001). Stepwise multivariable linear regression identified SEVR, AP and Aix@75 as independent correlates of estimated 10‐year ASCVD risk (p < 0.001). In conclusion, SEVR, AP and Aix@75 are independent correlates of estimated 10‐year ASCVD risk, and together provide a functional hemodynamic profile that independently correlates with estimated risk beyond traditional factors, suggesting their potential role as supplementary tools for cardiovascular risk stratification. These findings offer a valuable supplemental approach for improving cardiovascular risk assessment in clinical practice.Keywords: 10‐year atherosclerotic cardiovascular disease risk, augmentation index, augmentation pressure, hemodynamics, subendocardial viability index Abbreviations 10 Year Atherosclerotic Cardiovascular Disease Risk Augmentation index corrected for heart rate Augmentation Pressure Body Mass Index Body Mass Index Central Blood Pressure Cardiovascular Diseases Diastolic Blood Pressure Diastolic Pressure Time Index Fasting Blood Glucose High‐Density Lipoprotein High‐Density Lipoprotein Cholesterol Heart Rate Inter‐Ventricular Septum Low‐Density Lipoprotein Left Ventricular Left Ventricular Ejection Fraction Left Ventricular Mass Peripheral Artery Disease Posterior Wall Diastolic Thickness Posterior Wall Systolic Thickness Pulsed Wave Velocity Systolic Blood Pressure Subendocardial Viability Ratio Systolic Pressure Time Index Total Cholesterol Triglycerides Introduction Cardiovascular diseases (CVDs), in particular ischemic heart disease, are one of the major threats to human survival and quality of life in today's world, claiming approximately 17.7 million lives annually [1]. In most cases, ischemic heart disease is caused by atherosclerotic plaque–related coronary artery disease [2]. To enable more accurate identification of high‐risk individuals prior to the manifestation of clinical symptoms, the China‐PAR project has developed a 10‐year ASCVD risk prediction tool tailored for the Chinese population, derived from extensive domestic epidemiological data [3]. This type of model holds significant value at the population level. However, they mainly rely on traditional risk factors and have limitations in assessing the pathological and physiological aspects of individuals, especially in the early stage of heart function impairment in atherosclerotic heart disease. The increase of arterial stiffness observed in ASCVD patients may have a major role [4] [5]. Increased arterial stiffness increases the velocity of both forward and reflected pulse waves. This increase in pulsed wave velocity (PWV) causes arrival of reflected waves at the aorta during systole, and not during diastole, as it occurs under conditions of normal aortic elastic properties. The early arrival of the reflected waves causes 1.augmentation of the systolic aortic pressure, and thus, an increase of left ventricular afterload, wall stress, and cardiac workload leading to increased left ventricular mass and myocardial oxygen demands; and 2.reduction in the diastolic aortic pressure resulting in reduced myocardial perfusion [6]. And coronary circulation dysfunction can also lead to reduced myocardial perfusion, causing damage to myocardial cell metabolism and ischemia. The increase in arterial stiffness and coronary microcirculation dysfunction produced a cumulative effect, jointly forming a vicious cycle that exacerbates each other, promoting the progression of subclinical cardiac damage. Therefore, it is urgent for clinical practice to have assessment indicators that can early and directly reflect this pathological physiological process. Buckberg et al. [7] confirmed the extreme susceptibility of the subendocardium to factors that increase myocardial oxygen demand and/or restrict blood supply. They coined the term “subendocardial viability ratio” (SEVR), which reflects the balance between myocardial oxygen supply and demand and serves as an effective and accurate indicator of myocardial perfusion [8]. It is defined as the ratio of the diastolic pressure time index (DPTI) to the systolic pressure time index (SPTI). Early invasive hemodynamic studies in animals demonstrated that SPTI reflects myocardial oxygen demand [9], with a higher SPTI value indicating greater myocardial oxygen consumption and an increased risk of myocardial ischemia [10]. DPTI is an important determinant of subendocardial perfusion, reflecting myocardial oxygen supply [11]. Therefore, a low SEVR indicates a severe imbalance between myocardial oxygen supply and demand, suggesting reduced subendocardial myocardial perfusion [12]. Currently, SEVR is obtained by noninvasive methods, typically derived from radial artery applanation tonometry using a validated transfer function to estimate central aortic pressure waveforms, with the area under the diastolic portion of the central pressure waveform estimated as DPTI and the area under the systolic portion as a surrogate for SPTI [13]. This approach has been widely validated as a practical noninvasive alternative to invasive catheter‐based measurements [14]. Pulse wave analysis (PWA) enables the morphological analysis of the central arterial pressure waveform through noninvasive recording of pressure waveforms. AP and Aix@75 are measures of pressure wave reflection, defined as the aortic systolic pressure attributed to the reflected wave. These parameters are influenced by both peripheral vascular resistance and large artery stiffness, and have been validated as markers of early vascular dysfunction and predictors of subclinical cardiovascular risk in asymptomatic individuals [15, 16]. However, the current studies on the relationship between these indicators and age evolution as well as the comprehensive ASCVD risk score are not sufficiently comprehensive. We hypothesize that SEVR will decrease with age, while AP and Aix@75—as measures of pressure wave reflection—will increase with age, and all three are independent correlates of estimated 10‐year ASCVD risk. The purpose of this study is to explore the relationship between factors such as myocardial viability rate, AP, and Aix@75, and age and cardiovascular disease risk. Method Study Design and Patients We enrolled 3354 subjects from the Jiading Branch of Shanghai General Hospital, China, between March 2022 and March 2025. Inclusion criteria required participants to be aged between 18 and 80 years; a left ventricular ejection fraction (LVEF) >55%. Exclusion criteria were: (1) acute illness or any condition that could acutely influence hemodynamic parameters; (2) current hemodialysis or presence of arterio‐venous fistula; (3) upper‐limb infection, trauma, amputation, or inability to place the measurement cuff; (4) non‐palpable radial artery pulse or hand tremor interfering with signal acquisition; (5) atrial fibrillation or other significant arrhythmias (e.g., frequent premature beats, marked sinus arrhythmia) preventing stable pulse wave acquisition; (6) pacemaker dependency; (7) moderate‐to‐severe valvulopathies—particularly aortic stenosis—or severe aortic valve stenosis; (8) clinically relevant arterial stenosis between the measurement sites; (9) left ventricular ejection fraction <50% or overt heart failure; (10) BMI ≥40 kg/m2; and (11) pregnancy. These criteria were adopted based on established recommendations for pulse wave analysis (PWA) and arterial stiffness measurements. Written informed consent was obtained from all participants following a detailed explanation of the study objectives and procedures; all clinical examinations were performed in compliance with the Declaration of Helsinki. The study was approved by the Ethics Committee of Shanghai General Hospital (approval number: No. 2021KY057) and registered on the official website of the China Clinical Trial Registration Center (ChiCTR2000035937). Baseline Measurements Physical examinations and laboratory analyzes were conducted on the same day as enrollment. General information, including age, smoking habits, alcohol habits (defined as current drinking, i.e., consuming alcohol at least once per week within the past 12 months), history of hypertension, diabetes, and medication use, was collected through an electronic questionnaire. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2). Biochemical Assays Participants were instructed to fast for at least 12 h before venous blood sampling. On the following morning, 5 mL of venous blood was collected. Blood tests and biochemical assays were performed to measure total cholesterol (TC), triglycerides (TG), high‐density lipoprotein (HDL), low‐density lipoprotein (LDL) cholesterol, and fasting blood glucose (FBG) levels. Baseline Echocardiography A commercially available system (EPIQ7, Philips, S5 probe, Amsterdam, Netherlands) with a frequency range of 1–5 MHz, a frame rate of ≥60 frames/sec, and an inspection depth of 13–16 cm was used to acquire the original images, following the guidelines of the American Society of Echocardiography (ASE, 2015) [17]. The 2D echocardiographic images were obtained from parasternal long‐axis and short‐axis views, as well as from the three standard apical views. Transmitral blood flow was recorded in the apical four‐chamber view using pulsed‐wave Doppler, and the E wave velocity, peak velocity of late filling (A), and the E/A ratio were measured. Tissue Doppler imaging was used at the septum and lateral annulus, and e' was measured to calculate the E/e' ratio. Transthoracic acquisitions of three consecutive long‐axis images (apical four‐chamber, three‐chamber, and two‐chamber) were performed during image capture, with careful attention to ensure the absence of arrhythmia during the process. Hemodynamic Assessment and Definitions Before the measurements, participants rested for 5–10 min and were advised to refrain from smoking and avoid caffeine for at least 24 h. Measurements were obtained with participants in a seated position, in a quiet, temperature‐controlled room (24–26°C). The cuff was placed on one upper arm, with the bladder mark aligned to the brachial artery and the lower edge positioned 2–3 cm above the antecubital crease. Noninvasive measurements were performed using the SphygmoCor System (AtCor Medical Pty Ltd., West Ryde, Australia) [18, 19]. AP was defined as the difference between the second and the first systolic peak of the derived aortic pressure waveform, reflecting the magnitude of pressure wave reflection. Aix@75 was defined as the difference between the second and first systolic peaks of the central arterial waveform, expressed as a percentage of the central pulse pressure and corrected for heart rate to 75 beats per minute (Aix@75); it serves as an integrated measure of wave reflection influenced by both peripheral vascular resistance and large artery stiffness. The SEVR (also known as the Buckberg index), a functional index of myocardial oxygen supply‐demand balance, was calculated with pulse wave analysis and expressed as the ratio of the DPTI and SPTI (Figure 1)[8]. The measurement method of subendocardial viability ratio (SEVR). SEVR = diastolic pressure time index (DPTI)/systolic pressure time index (SPTI). The DPTI is the area under the diastolic central artery pressure curve, and the SPTI is the area under the systolic central artery pressure curve. All PWA recordings were performed in accordance with the SphygmoCor device's manufacturer‐recommended quality control standards and were accepted only if they met the following prespecified criteria: a sharp, nearly linear initial upstroke of the pressure waveform lasting for at least 80 ms; a clearly identifiable systolic and diastolic phase with a discernible dicrotic notch; and an in‐device operator index ≥ 80%. Recordings with excessive beat‐to‐beat variability, visible movement artifacts, or an operator index below the threshold were immediately discarded and repeated after a 2‐minute rest period. All measurements were performed by two trained physicians who had undergone standardized training and passed a reproducibility test prior to the study. Prediction of 10‐year ASCVD Risk In this study, the 10‐year ASCVD risk score developed by the Prediction for ASCVD Risk in China (China‐PAR) project was employed to assess participants' cardiovascular risk. This model was established by Yang et al. based on prospective cohort data comprising 21,320 Chinese adults and was externally validated in two independent Chinese cohorts (totaling 84,961 participants), demonstrating superior predictive performance for the Chinese population compared to Western conventional models such as the Pooled Cohort Equations [3]. The calculated 10Y‐ASCVDR reflects the estimated probability of developing a first ASCVD event within the next 10 years. The variables required for risk assessment included: age, sex, systolic blood pressure, diastolic blood pressure, TC, high‐density lipoprotein cholesterol (HDL‐C), current smoking status (yes/no), diagnosis of diabetes (yes/no), use of antihypertensive medication (yes/no) and family history of ASCVD. A 10Y‐ASCVDR <10% was defined as low risk, while a value ≥10% was defined as high risk; these thresholds have clinical relevance. Statistical Analysis for Reproducibility Two physicians independently assessed SEVR, AP and Aix@75 values for a cohort of 40 randomly selected participants to evaluate the reproducibility of the measurements. The sample size of 40 was determined based on established methodological recommendations for reliability and reproducibility studies [20, 21], which suggest that 20 to 30 participants are generally adequate for pilot reproducibility assessments . To further enhance the generalizability of our reproducibility findings, we extended the sample size to 40 participants. Inter‐observer agreements were evaluated using Bland‐Altman plots and linear regression analysis (Figure 2). Inter‐observer reproducibility of SEVR, AP, and Aix@75. A: Bland‐Altman plot for inter‐observer reproducibility of SEVR. The mean difference of SEVR inter‐observer measurements was 2.30, with 95% limits of agreement (95% LoA) ranging from ‐29.41 to 34.01. B: Linear regression between SEVR measurements by observer 1 and observer 2. The regression equation was Y = 0.7879X+30.60 (R2 = 0.56, p<0.001). C: Bland‐Altman plot for inter‐observer reproducibility of AP. The mean difference of AP inter‐observer measurements was 0.01, with 95% LoA ranging from ‐9.64 to 9.64. D: Linear regression between AP measurements by observer 1 and observer 2. The regression equation was Y = 0.7516X+2.608 (R2 = 0.58, P<0.001). E: Bland‐Altman plot for inter‐observer reproducibility of Aix@75. The mean difference of Aix@75 inter‐observer measurements was 0.33, with 95% LoA ranging from ‐12.71 to 13.38. F: Linear regression between Aix@75 measurements by observer 1 and observer 2. The regression equation was Y = 0.8035X+4.815 (R2 = 0.59, P<0.001). Statistical Analysis For normally distributed values, the data were presented as mean and standard deviation for continuous variables and one‐way analysis of variance and post hoc least‐significant difference analysis was used to present the clinical characteristics, anthropometric measures, and biochemical parameters for each age group when significant. For non‐normally distributed values, data were presented as median (along with first‐third quartiles). For categorical variables, the data were presented as numbers and percentages by category for qualitative variables and the Chi‐square test used for the descriptive analysis. A two‐tailed p value of less than 0.05 was considered statistically significant. Statistical analyzes were performed using statistical tools package SPSS 23.0 (IBM, Armonk, NY, USA). RCS statistical analyzes were performed using Stata 12 (Stata Corp, College Station, TX, USA). Result Baseline Characteristics A total of 3354 patients were included in the study. 56.6% (1,899) were female, 5.9% (201) were current smokers, and 1.6% (57) had alcohol consumption data. Patients were stratified into three age groups: 1,131 (33.7%) aged 18–44 years, 908 (27.1%) aged 45–59 years, and 1,315 (39.2%) aged≥60 years. Significant differences were observed across age groups for most variables. Notably, BMI, SBP, DBP, HR and CBP in middle‐aged and older patients were significantly higher than those in younger patients. As expected, the prevalence of established cardiovascular risk factors and comorbidities increased markedly with advancing age. The prevalence of diabetes and hypertension was significantly higher in the older groups (all P < 0.001), leading to a correspondingly higher use of Anti‐diabetic and anti‐hypertensive medication in the older groups (all P < 0.001). In addition, ≥60‐y group showed significantly elevated 10Y‐ASCVDR scores than the other two groups (p < 0.001) (Table 1). TABLE 1Basic characteristics of the study population.Variables 18‐44 years age n = 1131 45‐59years age n = 908 ≥60 years age n = 1315 F/χ2 p valueSex, female668(59.1%)522(57.5%)709(53.5%)6.940.031BMI, kg/m2 23.76 ± 4.3424.65 ± 3.65 * 23.74 ± 3.43 * 18.56<0.001Systolic blood pressure, mmHg123.02 ± 17.57133.82 ± 20.67 * 142.33 ± 20.53 [Link] , [Link] 387.27<0.001Diastolic blood pressure, mmHg82.75 ± 11.8085.94 ± 12.07 * 83.78 ± 11.42 ** 32.28<0.001Heart rate, beats/min81.02 ± 12.6876.21 ± 11.72 * 76.57 ± 12.71 * 72.10<0.001Central Blood Pressure, mmHg112.24 ± 17.02124.98 ± 19.43 * 131.99 ± 21.07 [Link] , [Link] 406.62<0.001Alcohol consumption, n 12(1.8%)13(2.4%)32(3.5)4.750.093Current Smoking, n37(3.3%)61(6.7%)103(7.8%)23.62<0.001Diabetes Mellitus, n21(1.9%)33(3.6%)92(7.0%)40.12<0.001Hypertension, n373(33.0%)479(52.8%)738(56.1%)144.88<0.001Antidiabetic, n30(2.7%)94(10.4%)295(22.4%)222.85<0.001Antihypertension, n46(4.1%)182(20.0%)589(44.8%)559.86<0.001SEVR137.49 ± 26.09139.23 ± 23.49 * 130.51 ± 23.83 ** 67.91<0.001AP, mmHg5.97 ± 5.0310.97 ± 6.54 * 14.21 ± 7.74 [Link] , [Link] 408.95<0.001Aix@75 (%)18.31 ± 12.3126.37 ± 11.62 * 27.27 ± 10.03 * 269.95<0.00110Y‐ASCVD0.86 ± 1.234.40 ± 2.95 * 13.36 ± 7.78 [Link] , [Link] 2626.68<0.001Abbreviations: BMI, body mass index; SEVR, subendocardial viability ratio; AP, augmentation pressure; Aix@75, Augmentation index corrected for heart rate; 10Y‐ASCVDR, 10‐year atherosclerotic cardiovascular disease risk.Compared with the group18‐44years old, * p < 0.05.Compared with the group 45–59years old, ** p < 0.05. Basic characteristics of the study population. 18‐44 years age n = 1131 45‐59years age n = 908 ≥60 years age n = 1315 Abbreviations: BMI, body mass index; SEVR, subendocardial viability ratio; AP, augmentation pressure; Aix@75, Augmentation index corrected for heart rate; 10Y‐ASCVDR, 10‐year atherosclerotic cardiovascular disease risk. Compared with the group18‐44years old, * p < 0.05. Compared with the group 45–59years old, ** p < 0.05. Reproducibility analysis in 40 randomly selected participants demonstrated good inter‐observer agreement for SEVR, AP and Aix@75 measurements. The mean biases were 2.3 for SEVR, 0.01 for AP, and 0.33 for Aix@75. The corresponding 95% limits of agreement were 34.0 to ‐29.4 for SEVR, 9.64 to ‐9.64 for AP, and 13.38 to ‐12.71 for Aix@75. These findings confirmed the robustness of the measurements and supported the reliability of subsequent analyzes (Figure 2). Hematological Parameters and Echocardiography Parameters Test Laboratory parameters among the three age groups are summarized in Table 2. Significant differences in red blood cell count (RBC), hemoglobin, and glomerular filtration rate (GFR) were observed across participants aged 18–44 years (n = 1131), 45–59 years (n = 908), and ≥60 years (n = 1315) (all P < 0.05). TABLE 2Descriptive statistics of laboratory parameter.Variables 18‐44 years age n = 1131 45‐59years age n = 908 ≥60 years age n = 1315 F/χ2 p valueWBC, ×1012 /L7.38 ± 3.607.28 ± 5.456.88 ± 4.26 * 2.390.092RBC, ×1012 /L4.69 ± 0.604.63 ± 0.544.39 ± 0.60 [Link] , [Link] 50.69<0.001Hemoglobin, g/L138.05 ± 20.04138.55 ± 19.04133.55 ± 17.22 [Link] , [Link] 15.20<0.001GFR, mL/min118.05 ± 35.22102.84 ± 42.52 * 93.73 ± 31.64 * 6.670.002Total cholesterol, mmol/L4.55 ± 0.994.58 ± 1.104.38 ± 1.15 [Link] , [Link] 4.550.011Triglyceride1.66 ± 1.291.67 ± 1.181.51 ± 1.00 ** 3.160.043LDL cholesterol, mmol/L2.79 ± 0.842.79 ± 0.952.63 ± 0.964.540.011HDL cholesterol, mmol/L1.19 ± 0.311.22 ± 0.331.18 ± 0.33 [Link] , [Link] 1.770.171Blood Glucose, mmol/L5.51 ± 1.745.73 ± 1.745.95 ± 1.90 * 5.580.004BNP, pg/mL26.07 ± 35.7151.33 ± 95.25 * 59.22 ± 67.88 * 4.870.008Abbreviation: WBC, White Blood Cell; RBC, Red Blood Cell; GFR, Glomerular Filtration Rate; LDL, low density lipoprotein; HDL, high density lipoprotein; BNP, B‐type Natriuretic Peptide.Compare with the group 18‐44 years old, * p < 0.05.Compared with the group 45–59 years old, ** p < 0.05. Descriptive statistics of laboratory parameter. 18‐44 years age n = 1131 45‐59years age n = 908 ≥60 years age n = 1315 Abbreviation: WBC, White Blood Cell; RBC, Red Blood Cell; GFR, Glomerular Filtration Rate; LDL, low density lipoprotein; HDL, high density lipoprotein; BNP, B‐type Natriuretic Peptide. Compare with the group 18‐44 years old, * p < 0.05. Compared with the group 45–59 years old, ** p < 0.05. Table 3 presents echocardiographic parameter measurements. The inter‐ventricular septum (IVS) thickness was significantly greater in the ≥ 60‐y group compared to the 45–59‐y and 18–44‐y groups (15.31 ± 1.62 mm vs. 14.62 ± 1.63 mm vs. 13.88 ± 2.10 mm, respectively; P < 0.001). Age‐related variations were observed in these echocardiographic parameters: posterior wall diastolic thickness (PWd) increased across age groups (18–44y: 9.04 ± 0.86 mm; 45–59y: 9.53 ± 0.87 mm; ≥ 60‐y: 9.59 ± 0.73 mm; p < 0.05), posterior wall systolic thickness (PWs) showed comparable progression (18–44y: 12.78 ± 1.27 m/s; 45–59y: 13.71 ± 1.26 m/s; ≥ 60y: 13.59 ± 2.04 m/s; p < 0.05), left ventricular mass (LVM) exhibited elevated values in older cohorts (18–44y: 144.50 ± 31.28 g; 45–59y: 162.49 ± 33.20 g; ≥60y: 162.07 ± 35.97 g; p < 0.05). TABLE 3Basic characteristics of the echocardiography.Variables 18‐44 years age n = 1131 45‐59years age n = 908 ≥60 years age n = 1315 F/χ2 p valueIVSd, mm9.40 ± 0.8510.10 ± 1.05 * 10.18 ± 1.10 * 0.620.540LVDd, mm45.88 ± 4.3946.93 ± 3.5246.59 ± 4.230.640.527PWd, mm9.04 ± 0.869.53 ± 0.87 * 9.59 ± 0.73 * 5.910.003IVSs, mm13.88 ± 2.1014.62 ± 1.6315.31 ± 1.62 [Link] , [Link] 8.82<0.001LVDs, mm27.83 ± 3.0228.25 ± 4.4528.34 ± 3.130.420.656PWs, m/s12.78 ± 1.2713.71 ± 1.26 * 13.59 ± 2.04 * 3.180.044LVEF, %69.38 ± 4.0368.28 ± 4.3968.48 ± 7.560.320.724FS, %38.97 ± 3.2038.19 ± 3.4038.79 ± 4.880.420.661PW, %39.84 ± 13.8143.70 ± 12.4238.74 ± 10.76 [Link] , [Link] 2.790.064LVM, g144.50 ± 31.28162.49 ± 33.20 * 162.07 ± 35.97 * 3.460.034 Note: Echocardiography, the index of left ventricular structure and function were obtained by Echocardiography;.Abbreviations:IVSd, interventricular septum diastolic thickness; LVDd, left ventricular diastolic dimension; PWd, posterior wall diastolic thickness; IVSs, interventricular septum systolic thickness; LVDs, left ventricular systolic dimension; PWs, posterior wall systolic thickness. LVEF, left ventricular ejection fraction; FS, fractional shortening; PW, posterior wall thickening percentage. LVM, left ventricular mass.Compared with the group 18‐44 years old, * p < 0.05.Compared with the group 45–59 years old, ** p < 0.05. Basic characteristics of the echocardiography. 18‐44 years age n = 1131 45‐59years age n = 908 ≥60 years age n = 1315 Note: Echocardiography, the index of left ventricular structure and function were obtained by Echocardiography;. Abbreviations:IVSd, interventricular septum diastolic thickness; LVDd, left ventricular diastolic dimension; PWd, posterior wall diastolic thickness; IVSs, interventricular septum systolic thickness; LVDs, left ventricular systolic dimension; PWs, posterior wall systolic thickness. LVEF, left ventricular ejection fraction; FS, fractional shortening; PW, posterior wall thickening percentage. LVM, left ventricular mass. Compared with the group 18‐44 years old, * p < 0.05. Compared with the group 45–59 years old, ** p < 0.05. Correlations Between SEVR, AP, Aix@75 and Clinical Index In univariable analysis, SEVR showed inverse correlations with heart rate (r = ‐0.630, P < 0.001), and SBP (r = ‐0.212, P < 0.001). Additionally, stepwise multivariable linear regression identified HR and SBP as independent predictors of SEVR (P < 0.001) (Table 4). TABLE 4Univariable and multivariable predictors of subendocardial viability ratio.Simple correlation analysisMultiple linear regression analysis (stepwise)Item r p‐valueRegression coefficient (β)Standardized coefficients (β′) p‐valueAge−0.134<0.001−0.068−0.0320.750BMI0.0010.979−0.715−−HR−0.630<0.001−1.437−0.607<0.001SBP−0.212<0.001−0.731−0.592<0.001DBP−0.0400.0531.039−−PWd−0.0720.4062.648−−IVSs0.0150.8601.278−−PWs−0.0410.6360.027−−LVM0.0450.6050.027−−Abbreviations: BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastole blood pressure; PWd, posterior wall diastolic thickness; IVSs, interventricular septum systolic thickness; PWs, posterior wall systolic thickness. LVM, left ventricular mass. Univariable and multivariable predictors of subendocardial viability ratio. Abbreviations: BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastole blood pressure; PWd, posterior wall diastolic thickness; IVSs, interventricular septum systolic thickness; PWs, posterior wall systolic thickness. LVM, left ventricular mass. Table 5 presents correlation analyzes between AP and clinical index. In univariable analysis, AP showed inverse correlations with HR (r = ‐0.478, P < 0.001), as well as a positive correlation with BMI (r = 0.126, p < 0.001), SBP (r = 0.579, p < 0.001), DBP (r = 0.048, P <0.05) and PWd (r = 0.236, P <0.05). The regression analysis showed that HR, SBP and DBP were independently associated with the AP (p < 0.001). TABLE 5Univariable and multivariable predictors of Augmentation Pressure.Simple correlation analysisMultiple linear regression analysis (stepwise)Item r p‐valueRegression coefficient (β)Standardized coefficients (β′) p‐valueAge0.512<0.001−0.022−0.0340.669BMI0.126<0.0010.1220.0360.494HR−0.478<0.001−0.329−0.3890.000SBP0.579<0.0010.4371.1450.000DBP0.0480.044−0.475−0.7640.000PWd0.2360.019−0.297−0.0280.670IVSs0.0340.738−0.742−−PWs0.1880.0610.495−−LVM0.0720.474−0.021−−Abbreviation: BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastole blood pressure; PWd, posterior wall diastolic thickness; IVSs, interventricular septum systolic thickness; PWs, posterior wall systolic thickness. LVM, left ventricular mass. Univariable and multivariable predictors of Augmentation Pressure. Abbreviation: BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastole blood pressure; PWd, posterior wall diastolic thickness; IVSs, interventricular septum systolic thickness; PWs, posterior wall systolic thickness. LVM, left ventricular mass. Table 6 presents correlation analyzes between Aix@75 and clinical index. In univariable analysis, Aix@75 showed inverse correlations with HR (r = ‐0.581, P < 0.001), as well as a positive correlation with BMI (r = 0.108, p < 0.001), SBP (r = 0.286, p < 0.001). The regression analysis showed that SBP was independently associated with the Aix@75 (p < 0.001). TABLE 6Univariable and multivariable predictors of Augmentation index corrected for heart rate.Simple correlation analysisMultiple linear regression analysis (stepwise)Item r p‐valueRegression coefficient (β)Standardized coefficients (β′) p‐valueAge0.351<0.001−0.010−0.0120.913BMI0.108<0.0010.2350.0570.429HR−0.581<0.001−0.508−0.5120.000SBP0.286<0.0010.3770.7770.000DBP−0.0340.108−0.404_−PWd0.1250.155−0.341_−IVSs−0.0480.584−1.453_−PWs0.1680.0540.707_−LVM0.0520.556−0.003_−Abbreviations: BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastole blood pressure; PWd, posterior wall diastolic thickness; IVSs, interventricular septum systolic thickness; PWs, posterior wall systolic thickness. LVM, left ventricular mass. Univariable and multivariable predictors of Augmentation index corrected for heart rate. Abbreviations: BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastole blood pressure; PWd, posterior wall diastolic thickness; IVSs, interventricular septum systolic thickness; PWs, posterior wall systolic thickness. LVM, left ventricular mass. Correlations Between AP, Aix@75, SEVR and Age The trends of AP, Aix@75, and SEVR with age are shown in Figure 3. Visual analysis revealed a significant positive relationship between AP and age in both female and male groups (R2 = 0.278, 0.250, p < 0.001, respectively). Similarly, Aix@75 showed a significant positive relationship with age (R2 = 0.133, 0.127, p < 0.001, respectively). In contrast, SEVR was inversely related to age (R2 = 0.016, 0.031, p < 0.001, respectively). Scatter plots and linear regression curves of AP, Aix@75 and SEVR with age. (A) There was a positive, statistically significant relationship between AP and Age in female and male groups (R2 = 0.278, 0.250, p < 0.001, respectively). (B) There was an positive, statistically significant relationship between Aix@75 and Age in female and male groups (R2 = 0.133, 0.127, p < 0.001, respectively). (C) There was an inverse, statistically significant relationship between SEVR and Age in female and male groups (R2 = 0.016, 0.031, p < 0.001, respectively). SEVR, subendocardial viability ratio, AP, augmentation pressure, Aix@75, augmentation index corrected for heart rate. These trends were strongly supported by the univariable correlation analysis. As detailed in Tables 4, 5, and 6, age demonstrated significant positive correlations with both AP (r = 0.512, p < 0.001) and Aix@75 (r = 0.351, p < 0.001), and a significant inverse correlation with SEVR (r = ‐0.134, p < 0.001). Correlations Between SEVR, AP, Aix@75 and 10Y‐ASCVD In univariable analysis, ASCVD showed inverse correlations with SEVR (r = ‐0.171, P < 0.001) as well as a positive correlation with AP (r = 0.452, p < 0.001), Aix@75 (r = 0.236, p < 0.001). Additionally, stepwise multivariable linear regression identified SEVR, AP and Aix@75 as independent correlates of estimated 10‐year ASCVD risk (P < 0.001) (Table 7). TABLE 7Correlation coefficients between 10Y‐ASCVD and SEVR, AP, AIX.ItemSimple correlation analysisMultiple linear regression analysis (stepwise) r p‐valueRegression coefficient (β)Standardized coefficients (β′) p‐valueSEVR−0.171<0.0010.007−0.092<0.001AP0.452<0.0010.0400.834<0.001Aix@750.236<0.0010.026−0.445<0.001 Note: SEVR, subendocardial viability ratio; AP, augmentation pressure; Aix@75, Augmentation index corrected for heart rate. Correlation coefficients between 10Y‐ASCVD and SEVR, AP, AIX. Note: SEVR, subendocardial viability ratio; AP, augmentation pressure; Aix@75, Augmentation index corrected for heart rate. Discussion In this study, we correlated the cardiovascular indicators such as SEVR, AP, and Aix@75 with a comprehensive and forward‐looking risk score (ASCVD risk), going beyond traditional risk factors and providing a new perspective for risk assessment. Our research has revealed that SEVR is negatively correlated with the risk of ASCVD, which is in complete accordance with physiological expectations. Coronary blood flow is influenced by myocardial contractility; during systole, left ventricular (LV) pressure reaches its peak, resulting in maximal resistance to subendocardial coronary perfusion and minimal or even complete cessation of coronary blood flow. Subendocardial myocardial perfusion is almost entirely dependent on diastolic coronary perfusion and the duration of diastole, which are reflected by the DPTI [11]. SEVR is defined as the ratio of the DPTI to the SPTI. Therefore, a low SEVR indicates a severe imbalance between myocardial oxygen supply and demand, suggesting reduced subendocardial myocardial perfusion. This imbalance is the core aspect of myocardial ischemia. Therefore, the lower the SEVR, the higher the risk of future ASCVD events for an individual. Heart rate also has a significant negative effect on SEVR. SEVR gradually decreases with increasing resting heart rate, possibly because of the decrease in myocardial perfusion caused by shortening of the diastolic duration as a result of the increase in resting heart rate. This phenomenon has also been discovered in several papers [22, 23, 24]. AP and Aix@75 are measures of pressure wave reflection, which is determined by the interaction between large artery stiffness and peripheral vascular resistance. Meanwhile, both AP and Aix@75 showed a positive correlation with the risk of ASCVD. Aix@75 relies on the elastic supporting properties of the entire arterial tree (elastic arteries and muscular arteries). A larger Aix@75 value indicates an increase in reflected waves from the surroundings, or a more rapid return of reflected waves due to an increase in PWV (attributed to an increase in arterial stiffness). This enhanced wave reflection not only increases the afterload of the heart but may also impair coronary artery perfusion, thereby jointly raising the overall risk of ASCVD. Scandale et al. [25] studied 248 patients with peripheral artery disease (PAD) and 307 without PAD and found a significant negative correlation of SEVR with augmentation index corrected for heart rate and aortic pulse pressure in those with PAD. In a study of 75 elderly patients by Fantin et al. [26], there was also a significant negative correlation between SEVR and carotid‐femoral PWV. In summary, there is a close correlation between arterial stiffness and myocardial ischemia [27, 28], which also provides additional evidence for our research. Namasivayam et al. [29] investigated 3682 healthy individuals and found that their SEVR decreased gradually with age in both sexes, while Gómez‐Sánchez et al. [30] found that this change was more pronounced in men. With advancing age, the degradation of elastin and deposition of collagen in the aorta and its major branches lead to a progressive increase in arterial stiffness. An increase in stiffness will directly lead to an acceleration of the pulse wave conduction velocity, causing the reflected wave to return to the aorta earlier and reach the heart during the systolic phase rather than the diastolic phase [31]. This in turn led to an increase in AP and Aix@75, thereby increasing the afterload of the heart. At the same time, an increase in the stiffness of the large arteries would also lower diastolic blood pressure and shorten the diastolic perfusion time, jointly resulting in a decrease in SEVR (myocardial perfusion reserve [32]. Therefore, our findings suggest that SEVR, AP and Aix@75 may be important functional mediators at the biological level that link ‘age’ with ‘ASCVD risk’. In other words, the impact of age on cardiovascular risk is largely achieved by deteriorating these functional hemodynamic parameters. Additionally, global longitudinal strain (GLS) has emerged as a sensitive marker of subclinical myocardial dysfunction and may provide complementary information to SEVR in assessing myocardial stress. Future investigations incorporating GLS measurements are warranted to explore its correlation with SEVR and other hemodynamic parameters, which may further elucidate the interplay between functional hemodynamic alterations and myocardial deformation in the context of ASCVD risk stratification. It is also important to recognize that prescribed cardiovascular medications may influence PWA‐derived parameters. Different classes of antihypertensive agents exert differential effects on arterial stiffness and wave reflection. A meta‐analysis by Manisty et al. demonstrated that β‐blockers significantly increase augmentation index, whereas other antihypertensive drug classes—including angiotensin‐converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs)—reduce it to similar extents [33]. In the present study, medication use was not included as a covariate in the univariable analyzes; therefore, the potential confounding effects of medications on the associations between SEVR, AP, Aix@75 and estimated 10‐year ASCVD risk remain unclear. Future studies incorporating detailed medication profiling are warranted to further clarify this issue. The results of this study have significant potential clinical significance. By non‐invasively measuring these functional hemodynamic parameters, we may be able to optimize the existing ASCVD risk prediction models, especially for individuals whose traditional risk factors fall in the ‘borderline’ or ‘moderate‐risk’ category. Incorporating these functional indicators into the assessment process may help to more accurately identify truly high‐risk individuals, thereby enabling early intervention. Limitations This study still has some limitations. Firstly, it is a cross‐sectional study and cannot establish a causal relationship. Second, the single‐center nature of the study may introduce selection bias. Third, although patients with atrial fibrillation were excluded because stable PWA cannot be obtained, other arrhythmias were not systematically excluded and may affect measurement reproducibility. Fourth, carotid‐femoral pulse wave velocity (cf‐PWV)—the current reference standard for noninvasive assessment of arterial stiffness as recommended by both the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)—was not measured in this study. Instead, we employed AP and Aix@75 as surrogate markers of pressure wave reflection. We acknowledge that the absence of cf‐PWV constitutes a major methodological limitation, as AP and Aix@75, while reflecting wave reflection influenced by arterial stiffness, are not direct substitutes for cf‐PWV. Future studies incorporating direct cf‐PWV measurements are warranted to validate and extend our findings.Finally, we used 10‐year risk prediction scores rather than actual hard endpoint events. Future large‐scale prospective cohort studies are needed to confirm the independent predictive value of these parameters for ASCVD outcomes and to evaluate their added benefit in existing risk models. Conclusions In conclusion, this study has confirmed that the SEVR, AP and Aix@75 are independent correlates of estimated 10‐year ASCVD risk. These findings provide new evidence for using functional hemodynamic assessment as a powerful supplementary tool for cardiovascular risk stratification. Author Contributions Zhaojun Li and Xianghong Luo designed the research study and acquired funding. LY conceived the study and drafted the manuscript. LXW analyzed and interpreted data. Jing Ma, Ning Wang, Rong Yu, Tianyu Wu, Huiyong Hu, Hairong Wang, and Xianghong Luo reviewed and edited the manuscript. Jing Ma, Ning Wang, Rong Yu, Tianyu Wu, Huiyong Hu, Hairong Wang, and Xianghong Luo helped perform the analysis with constructive discussions. Lan Yang, Lingxiao Wang, Jing Ma, and Ning Wang provided administrative and data collection support. Zhaojun Li and Xianghong Luo helped obtain case acquisition and technical knowledge. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. Funding This work was supported by the National Natural Science Foundation of China (82472008), the Natural Science Foundation of Shanghai (21ZR1451400), and the Shanghai Health and Family Planning Commission Fund (202240235). Ethics Statement This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Shanghai General Hospital (No.2021KY057) and was officially registered with the China Clinical Trial Registration Center (Registration No. ChiCTR2000035937, 2020–8‐20, Shanghai General Hospital). Consent Written informed consent was obtained from all participants prior to their enrollment in the study. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting File 1 : jch70364‐sup‐0001‐SuppMat.docx Acknowledgments The authors would like to thank our team of physicians in this hospital who assisted in the follow‐up data collection. Contributor Information Xianghong Luo, Email: lxh_20050703@sina.com. Zhaojun Li, Email: lzj_1975@sina.com. Data Availability Statement The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. References Associated Data Supplementary Materials Supporting File 1 : jch70364‐sup‐0001‐SuppMat.docx Data Availability Statement The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.